Boston Scientific (NYSE:BSX) Board Declares Share Buyback Program

Boston Scientific (NYSE:BSX) declared that its Board of Directors has approved a stock repurchase plan on Monday, May 18th, RTT News reports. The company plans to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BSX shares. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a research report on Thursday, April 23rd. Raymond James Financial reissued an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Citigroup decreased their target price on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. JPMorgan Chase & Co. dropped their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Jefferies Financial Group cut their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $92.83.

Boston Scientific Stock Up 6.0%

BSX traded up $3.18 during trading on Monday, hitting $55.86. 16,765,349 shares of the company’s stock traded hands, compared to its average volume of 20,224,690. Boston Scientific has a 12-month low of $52.52 and a 12-month high of $109.50. The company’s 50 day simple moving average is $63.06 and its two-hundred day simple moving average is $81.33. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $83.02 billion, a price-to-earnings ratio of 23.37, a PEG ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts predict that Boston Scientific will post 3.38 earnings per share for the current fiscal year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific launched a $2 billion accelerated share repurchase, which should reduce share count and support earnings per share. The move signals management confidence and adds a near-term catalyst for the stock. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also announced a $1.5 billion strategic investment in MiRus, taking an approximately 34% stake and gaining an exclusive option to buy MiRus’ TAVR business. Investors view this as a way for Boston Scientific to expand into the fast-growing structural heart market. Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
• Positive Sentiment: Several analysts reiterated bullish views, including Needham and BTIG, both of which kept buy ratings and highlighted upside potential in BSX shares. Analyst rating updates
• Neutral Sentiment: Boston Scientific was also mentioned on a list of top analyst picks for the week, reflecting continued positive sentiment around the name. 3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
• Negative Sentiment: One notable offset is that Bank of America lowered its price target on BSX, even while keeping a buy rating, suggesting some caution about valuation or near-term expectations. Bank of America price target update

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.